Dynavax Technologies DVAX

HealthcareMarket cap $2B1 connection

Dynavax makes HEPLISAV-B - a two-dose hepatitis B vaccine that provides faster, stronger protection than the older three-dose Engerix-B. Its CpG 1018 adjuvant (immune stimulant) is also used in COVID vaccines (by Clover Biopharmaceuticals). Adjuvant technology is a platform that can enhance many vaccines beyond hepatitis.

Explore Dynavax Technologies on the interactive map Relationship timeline Find a path to another company

Partners 1

Strategic partnerships, joint products and alliances

PfizerHealthcare · $160BPfizer evaluates Dynavax CpG adjuvant for vaccines

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie Merck AstraZeneca Thermo Fisher Novartis Abbott Labs

Embed this on your site

Show Dynavax Technologies's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=DVAX" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Dynavax Technologies on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.